Billing and Coding: Intravenous Immune Globulin (IVIg)-NCD 250.3

CMS covers IVIg when the patient meets at least one of the following: failed conventional therapy, conventional therapy is contraindicated, or rapidly progressive disease requiring short-term IVIg alongside conventional therapy until those agents take effect. IVIg for autoimmune mucocutaneous blistering disease is limited to short-term use and is not covered as maintenance therapy; local contractors have discretion to define failure, contraindication, and short-term duration and may impose additional local requirements.

"IVIg is covered when the patient has failed conventional therapy for the treated condition."

Sign up to see full coverage criteria, indications, and limitations.